Your browser doesn't support javascript.
Molnupiravir: A new candidate for COVID-19 treatment.
Pourkarim, Fariba; Pourtaghi-Anvarian, Samira; Rezaee, Haleh.
  • Pourkarim F; Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Pourtaghi-Anvarian S; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rezaee H; Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmacol Res Perspect ; 10(1): e00909, 2022 02.
Article in English | MEDLINE | ID: covidwho-1588891
ABSTRACT
The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Cytidine / COVID-19 Drug Treatment / Hydroxylamines Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2022 Document Type: Article Affiliation country: Prp2.909

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Cytidine / COVID-19 Drug Treatment / Hydroxylamines Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Pharmacol Res Perspect Year: 2022 Document Type: Article Affiliation country: Prp2.909